Insulin glargine

Intervention1 paper

Human trial1

Latest

1

LancetHuman trial1 Oct

Cardiovascular safety of orforglipron versus insulin glargine in adults with type 2 diabetes at increased cardiovascular risk (ACHIEVE-4): a phase 3, event-driven, randomised, open-label, non-inferiority, active comparator trial